首页> 外文期刊>Journal of Clinical Microbiology >Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method
【24h】

Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method

机译:按需数字点胶方法提高了广谱β-内酰胺酶生产肠杆菌科的头孢吡肟药敏试验的准确性

获取原文
           

摘要

Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae generally cannot be treated with penicillins and cephalosporins. However, some later-generation cephalosporins, including cefepime, are poorly hydrolyzed by specific ESBL enzymes, and certain strains demonstrate in vitro susceptibility to these agents, potentially affording additional treatment opportunities. Moreover, the ability to adjust both the dose and dosing interval of beta-lactam agents allows the treatment of strains with elevated MICs that were formerly classified in the intermediate range. The ability to treat strains with elevated cefepime MICs is codified in new susceptible dose-dependent (SDD) breakpoints promulgated by the Clinical and Laboratory Standards Institute. In the interest of validating and implementing new cefepime SDD criteria, we evaluated the performances of Vitek 2, disk diffusion, and a MicroScan panel compared to that of reference broth microdilution (BMD) during the testing of 64 strains enriched for presumptive ESBL phenotype (based on nonsusceptibility to ceftriaxone). Surprisingly, categorical agreement with BMD was only 47.6%, 57.1%, and 44.6% for the three methods, respectively. Given these findings, we tested the performance of the HP D300 inkjet-assisted broth microdilution digital dispensing method (DDM), which was previously described by our group as an at-will testing alternative. In contrast to commercial methods, DDM results correlated well with the reference method, with 86% categorical agreement, 91.1% evaluable essential agreement, and no major or very major errors. The reproducibility and accuracy of MIC determinations were statistically equivalent to BMD. Our results provide support for the use of the DDM as a BMD equivalent methodology that will enable hospital-based clinical laboratories to support cefepime MIC-based dosing strategies.
机译:产生超广谱β-内酰胺酶(ESBL)的肠杆菌科细菌通常不能用青霉素和头孢菌素治疗。然而,某些下一代头孢菌素,包括头孢吡肟,被特定的ESBL酶水解不良,某些菌株对这些药物表现出体外敏感性,可能提供其他治疗机会。而且,调节β-内酰胺剂的剂量和给药间隔的能力允许治疗以前被分类为中等范围的具有升高的MIC的菌株。由临床和实验室标准协会发布的新的易感剂量依赖性(SDD)断点中阐明了治疗头孢吡肟MIC升高的菌株的能力。为了验证和实施新的头孢吡肟SDD标准,我们在测试64种富含ESBL表型推测菌株的过程中,评估了Vitek 2,纸片扩散和MicroScan面板与参考肉汤微稀释(BMD)相比的性能。对头孢曲松不敏感)。出乎意料的是,三种方法与BMD的分类一致性分别仅为47.6%,57.1%和44.6%。鉴于这些发现,我们测试了HP D300喷墨辅助肉汤微稀释数字分配方法(DDM)的性能,该方法先前被我们的小组描述为随意测试的替代方法。与商业方法相比,DDM结果与参考方法具有很好的相关性,分类一致性为86%,可评估的基本一致性为91.1%,没有重大或非常重大的错误。 MIC测定的重现性和准确性在统计学上等同于BMD。我们的结果为将DDM用作BMD等效方法提供了支持,这将使基于医院的临床实验室能够支持基于头孢吡肟MIC的给药策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号